Project/Area Number |
18K08602
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
Research Institution | Teikyo University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
砂村 眞琴 東京医科大学, 医学部, 兼任教授 (10201584)
杉本 昌弘 東京医科大学, 医学部, 教授 (30458963)
|
Project Period (FY) |
2018-04-01 – 2023-03-31
|
Project Status |
Completed (Fiscal Year 2022)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | 乳癌 / 血液 / 診断 / メタボローム / マルチオミックス |
Outline of Final Research Achievements |
We conducted comprehensive metabolite analysis of serum samples obtained from 66 breast cancer patients who had neoadjuvant chemotherapy, using capillary electrophoresis time-of-flight-mass spectrometry (CE-TOF-MS). 16 luminal, 33 HER2, and 17 tiple negative breast cancer were included. Pathological complete response (pCR) was found in 30 cases. One metabolite, 3-Indoxylsulfate was tended to be lower concentrations in pCR patients compared with non-pCR patients.
|
Academic Significance and Societal Importance of the Research Achievements |
メタボローム解析によって得られた効果予測マーカーを臨床情報と合わせて解析することにより、定量的かつ客観的な指標で癌を特徴化することができれば、化学療法の個別化や、さらには予後予測などへの活用も期待できる。医療の標準化で陥りやすい過剰医療を防ぎ、個別医療化に向けたマーカーを同時に探す研究例は、学術的な成果だけでなく、医療経済的なインパクトが高い。
|